LANTUS SOLOSTAR IN REAL LIFE MEDICAL PRACTICE

Abstract

Background and aims: The epidemic of diabetes mellitus has made the effective treatment of hyperglycemia a top priority. Maintaining near-normal glycemic levels has been demonstrated to have a beneficial effect on diabetes-specific complications. Insulin can decrease any level of elevated glycated hemoglobin. Insulin glargine (Lantus®) is a long-acting insulin analog with a favorable 24-h time-action profile, once daily administration and low risk of hypoglycemia used in type 1 and 2 diabetes. In Romania, real-life data about glycaemic control is lacking. Material and methods: We present results from a retrospective, open-label, non-randomised, registry trial in 2946 Romanian diabetes patients. The objective of the study was to assess the proportion of patients with appropriate glycaemic control after 3 to 6 months of glargine treatment. Results and conclusions: A little over one third of the patients had reached target glycated hemoglobin after 3-6 months of glargine treatment in both types of diabetes. In type 2 diabetes patients the glargine dose used was not high (0.33 UI/kg). Inadequate insulin titration is a possible cause for not reaching glycemic targets.